Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05465317 · ClinicalTrials.gov registry record
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
A clinical trial of Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 62,197
- Enrollment target
- 1
- Study location
NCT05465317 is a study of Diabetes Mellitus, Type 2 that has completed, run by Boehringer Ingelheim. The registered enrollment target is 62,197 participants, above the 4,307-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (1344% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05465317, a study of Diabetes Mellitus, Type 2, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 62,197 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus (T2DM) with and without established kidney disease. The secondary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of any Sodium glucose co-transporter-2 inhibitors (SGLT2i) compared to Glucagon-like Peptide-1 Receptor Agonists (GLP1RA) in patients with T2DM.
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Dipeptidyl Peptidate-4 inhibitors
Study Locations (1)
North Carolina
- Duke Clinical Research Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62,197 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2023-05-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05465317
The ClinicalTrials.gov registry entry for NCT05465317 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 62,197 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,307-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (1344% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT05465317 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05465317 about?
NCT05465317 is a clinical study titled "Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease". The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus (T2DM) with and without established kidney disease. The secondary purpose...
What is the current status of trial NCT05465317?
This trial is currently completed. The enrollment target is 62,197 participants. The study started on 2022-08-08. Estimated completion is 2023-05-02.
What conditions does trial NCT05465317 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT05465317?
The interventions under investigation include: Empagliflozin (DRUG), Dipeptidyl Peptidate-4 inhibitors (DRUG).
Who is sponsoring clinical trial NCT05465317?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05465317 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.